Caveolin-1 and-2 and their relationship to cerebral amyloid angiopathy in Alzheimer's disease

被引:34
|
作者
van Helmond, Z. K. [1 ]
Miners, J. S. [1 ]
Bednall, E. [1 ]
Chalmers, K. A. [1 ]
Zhang, Y. [1 ]
Wilcock, G. K. [1 ]
Love, S. [1 ]
Kehoe, P. G. [1 ]
机构
[1] Univ Bristol, Dementia Res Grp, Inst Clin Neurosci, Frenchay Hosp, Bristol BS16 1LE, Avon, England
关键词
Alzheimer's disease; amyloid beta peptide; caveolin-1; caveolin-2; cerebral amyloid angiopathy; tunica media;
D O I
10.1111/j.1365-2990.2006.00815.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Cerebral amyloid angiopathy (CAA) affects over 90% of patients with Alzheimer's disease (AD) and increases the risk of cerebral haemorrhage and infarction. Caveolae - cholesterol-enriched plasmalemmal microinvaginations - are implicated in the production of amyloid beta peptide (A beta). Caveolin-1 (CAV-1) is essential for the formation of caveolae. Caveolin-2 (CAV-2) is expressed at the plasma membrane only when in a stable hetero-oligomeric complex with CAV-1. CAV-1 and CAV-2 are highly co-expressed by endothelium and smooth muscle. Recent studies suggest that down-regulation of CAV-1 causes a reduction in alpha-secretase activity and consequent accumulation of A beta. We have used quantitative immunohistochemical techniques to assess the relationship between CAV-1 and CAV-2 with respect to A beta accumulation in the cerebral vasculature in a series of post mortem brains. CAV-1 and CAV-2 were co-expressed within the tunica media and endothelium of cerebral blood vessels. There were regional differences in CAV-1 immunolabelling, which was significantly greater in the frontal cortex and white matter than in the parietal lobe (in both control and AD cases) or the temporal lobe (in AD alone). However, CAV-1 labelling in AD did not differ from that in controls in any of the three lobes examined. Assessment of CAV-1 labelling in relation to the severity of CAA showed CAV-1 to be significantly increased in the frontal white matter in a subgroup of AD cases with absent/mild CAA compared with controls with absent/mild CAA and to AD cases with moderate/severe CAA, but the latter groups did not show significant differences from one another. CAV-1 labelling did not vary with age, gender, APOE genotype, post mortem delay or brain weight. Only segments of blood vessels with particularly abundant A beta and extensive loss of smooth muscle actin showed loss of CAV-1 and CAV-2 from the tunica media. Within these vessels endothelial CAV-1 was preserved and discontinuous CAV-2 labelling was noted along the outer aspect of the vessel wall. Our findings suggest that alterations in the expression of vascular CAV-1 and CAV-2 are unlikely to play a role in the development of CAA in AD.
引用
收藏
页码:317 / 327
页数:11
相关论文
共 50 条
  • [1] Cerebral amyloid angiopathy and its relationship to Alzheimer's disease
    Thal, Dietmar Rudolf
    Griffin, W. Sue T.
    de Vos, Rob A. I.
    Ghebremedhin, Estifanos
    ACTA NEUROPATHOLOGICA, 2008, 115 (06) : 599 - 609
  • [2] Cerebral amyloid angiopathy and its relationship to Alzheimer’s disease
    Dietmar Rudolf Thal
    W. Sue T. Griffin
    Rob A. I. de Vos
    Estifanos Ghebremedhin
    Acta Neuropathologica, 2008, 115 : 599 - 609
  • [3] The relationship between CAV-1 and cerebral amyloid angiopathy in Alzheimer's disease
    Chalmers, KA
    Zhang, YN
    Love, S
    Wilcock, GK
    Kehoe, PG
    NEUROBIOLOGY OF AGING, 2004, 25 : S156 - S156
  • [4] Relationship of neurofibrillary pathology to cerebral amyloid angiopathy in Alzheimer's disease
    Williams, S
    Chalmers, K
    Wilcock, GK
    Love, S
    NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 2005, 31 (04) : 414 - 421
  • [5] Relationship of neurofibrillary pathology to cerebral amyloid angiopathy in Alzheimer's disease
    Williams, S
    Chalmers, K
    Wilcock, GK
    Love, S
    NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 2005, 31 (02) : 242 - 242
  • [6] Cerebral amyloid angiopathy and Alzheimer's disease
    de Courten-Myers, GM
    NEUROBIOLOGY OF AGING, 2004, 25 (05) : 603 - 604
  • [7] ACE levels and activity in Alzheimer's disease, and relationship to cerebral amyloid angiopathy
    Miners, S.
    van Helmond, Z.
    Chalmers, K.
    Palmer, L.
    Love, S.
    Kehoe, P.
    NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 2007, 33 (02) : 263 - 263
  • [8] Relationship between cerebral amyloid angiopathy and CSF biomarkers in Alzheimer's disease
    Kanemaru, K.
    Sengoku, R.
    Nishina, Y.
    Murayama, S.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2017, 381 : 667 - 667
  • [9] Alzheimer's Disease and Cerebral Amyloid Angiopathy, Doppelgangers?
    Sarroukh, Rabia
    Hubin, Ellen
    Serpell, Louise C.
    van Nuland, Nico A.
    Broersen, Kerensa
    Raussens, Vincent
    PROTEIN SCIENCE, 2014, 23 : 86 - 86
  • [10] Contribution of cerebral amyloid angiopathy to Alzheimer's disease
    Love, S
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2004, 75 (01): : 1 - 4